Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 11 de 11
Filtrer
Plus de filtres










Base de données
Gamme d'année
1.
Biol Pharm Bull ; 47(4): 868-871, 2024.
Article de Anglais | MEDLINE | ID: mdl-38644197

RÉSUMÉ

Restoration of blood flow in skeletal muscle after a prolonged period of ischemia induces muscular ischemia-reperfusion injury, leading to local injury/dysfunction in muscles followed by systemic inflammatory responses. However, preventive/curative agents for skeletal muscle ischemia injury are unavailable in clinics to date. Increasing evidence has validated that carbon monoxide (CO) prevents the progression of ischemia-reperfusion injury in various organs owing to its versatile bioactivity. Previously, we developed a bioinspired CO donor, CO-bound red blood cells (CO-RBC), which mimics the dynamics of RBC-associated CO in the body. In the present study, we have tested the therapeutic potential of CO-RBC in muscular injury/dysfunction and secondary systemic inflammation induced by skeletal muscle ischemia-reperfusion. The results indicate that CO-RBC rather than RBC alone suppressed elevation of plasma creatine phosphokinase, a marker of muscular injury, in rats subjected to both hind limbs ischemia-reperfusion. In addition, the results of the treadmill walking test revealed a significantly decreased muscular motor function in RBC-treated rats subjected to both hind limbs ischemia-reperfusion than that in healthy rats, however, CO-RBC treatment facilitated sustained muscular motor functions after hind limbs ischemia-reperfusion. Furthermore, CO-RBC rather than RBC suppressed the production of tumour necrosis factor (TNF)-α and interleukin (IL)-6, which were upregulated by muscular ischemia-reperfusion. Interestingly, CO-RBC treatment induced higher levels of IL-10 compared to saline or RBC treatments. Based on these findings, we suggest that CO-RBC exhibits a suppressive effect against skeletal muscle injury/dysfunction and systemic inflammatory responses after skeletal muscle ischemia-reperfusion.


Sujet(s)
Monoxyde de carbone , Inflammation , Muscles squelettiques , Rat Sprague-Dawley , Lésion d'ischémie-reperfusion , Animaux , Lésion d'ischémie-reperfusion/traitement médicamenteux , Muscles squelettiques/effets des médicaments et des substances chimiques , Muscles squelettiques/métabolisme , Mâle , Inflammation/traitement médicamenteux , Érythrocytes/effets des médicaments et des substances chimiques , Érythrocytes/métabolisme , Rats , Creatine kinase/sang , Membre pelvien/vascularisation , Facteur de nécrose tumorale alpha/métabolisme , Facteur de nécrose tumorale alpha/sang , Interleukine-6/métabolisme , Interleukine-6/sang
2.
J Pharmacol Exp Ther ; 372(3): 355-365, 2020 03.
Article de Anglais | MEDLINE | ID: mdl-31924689

RÉSUMÉ

Many victims, after being extricated from a collapsed building as the result of a disaster, suffer from disaster nephrology, a term that is referred to as the crush syndrome (CS). Recommended treatments, which include dialysis or the continuous administration of massive amounts of fluid are not usually easy in cases of such mass natural disasters. In the present study, we examined the therapeutic performance of a biomimetic carbon monoxide (CO) delivery system, CO-enriched red blood cells (CO-RBCs), on experimental animal models of an acute kidney injury (AKI) induced by traumatic and nontraumatic rhabdomyolysis, including CS and rhabdomyolysis with massive hemorrhage shock. A single CO-RBC treatment was found to effectively suppress the pathogenesis of AKI with the mortality in these model rats being improved. In addition, in further studies using glycerol-induced rhabdomyolysis model rats, the pathogenesis of which is similar to that for the CS, AKI and mortality were also reduced as the result of a CO-RBC treatment. Furthermore, CO-RBCs were found to have renoprotective effects via the suppression of subsequent heme protein-associated renal oxidative injury; the oxidation of myoglobin in the kidneys, the generation of reactive oxygen species by free heme produced from degraded-cytochrome P450 and hemoglobin-associated renal injury. Because CO-RBCs can be prepared and used at both hospitals and at a disaster site, these findings suggest that CO-RBCs have the potential for use as a novel cell therapy against both nontraumatic and traumatic rhabdomyolysis including CS-induced AKI. SIGNIFICANCE STATEMENT: After mass natural and man-made disasters, people who are trapped in collapsed buildings are in danger of acute kidney injury (AKI), including crush syndrome (CS)-related AKI. This paper reports that carbon monoxide-enriched red blood cells (CO-RBCs), which can be prepared at both hospitals and disaster sites, dramatically suppressed the pathogenesis of CS-related AKI, thus improving mortality via suppressing heme protein-associated renal injuries. CO-RBCs have the potential for serving as a practical therapeutic agent against disaster nephrology associated with the CS.


Sujet(s)
Atteinte rénale aigüe/traitement médicamenteux , Monoxyde de carbone/usage thérapeutique , Syndrome d'écrasement/complications , Érythrocytes/composition chimique , Rein/effets des médicaments et des substances chimiques , Rhabdomyolyse/complications , Atteinte rénale aigüe/étiologie , Animaux , Apoptose/effets des médicaments et des substances chimiques , Monoxyde de carbone/administration et posologie , Modèles animaux de maladie humaine , Systèmes de délivrance de médicaments , Rein/métabolisme , Rein/anatomopathologie , Cellules LLC-PK1 , Stress oxydatif/effets des médicaments et des substances chimiques , Rat Sprague-Dawley , Analyse de survie , Suidae
3.
Sci Rep ; 5: 14471, 2015 Sep 28.
Article de Anglais | MEDLINE | ID: mdl-26412311

RÉSUMÉ

Rhabdomyolysis-associated acute kidney injury (AKI) is a serious life-threatening condition. As such, more effective strategies are needed for its prevention. Thioredoxin-1 (Trx), a redox-active and macrophage migration inhibitory factor (MIF) modulating protein, has a short retention time in the blood. We examined the renoprotective effect of long acting Trx that was genetically fused with human serum albumin (HSA-Trx) against glycerol-induced AKI. An intravenous HSA-Trx pre-treatment attenuated the glycerol-induced decline in renal function, compared to a PBS, HSA or Trx alone. HSA-Trx caused a reduction in the tubular injuries and in the number of apoptosis-positive tubular cells. Renal superoxide, 8-hydroxy deoxyguanosine, nitrotyrosine and the plasma Cys34-cysteinylated albumin were clearly suppressed by the HSA-Trx treatment. Prior to decreasing TNF-α and IL-6, HSA-Trx suppressed an increase of plasma MIF level. In LLC-PK1 cells, HSA-Trx decreased the level of reactive oxygen species and lactate dehydrogenase release induced by myoglobin. HSA-Trx treatment resulted in a threefold increase in the survival of lethal glycerol-treated mice. The post-administration of HSA-Trx at 1 and 3 hr after glycerol injection exerted a significant renoprotective effect. These results suggest HSA-Trx has potential for use in the treatment of rhabdomyolysis-associated AKI via its extended effects of modulating oxidative stress and MIF.


Sujet(s)
Atteinte rénale aigüe/étiologie , Atteinte rénale aigüe/métabolisme , Facteurs inhibiteurs de la migration des macrophages/métabolisme , Stress oxydatif/effets des médicaments et des substances chimiques , Agents protecteurs/pharmacologie , Rhabdomyolyse/complications , Thiorédoxines/pharmacologie , Atteinte rénale aigüe/traitement médicamenteux , Atteinte rénale aigüe/mortalité , Atteinte rénale aigüe/anatomopathologie , Animaux , Apoptose/effets des médicaments et des substances chimiques , Survie cellulaire/effets des médicaments et des substances chimiques , Cytokines/métabolisme , Modèles animaux de maladie humaine , Glycérol/effets indésirables , Médiateurs de l'inflammation/métabolisme , Tests de la fonction rénale , Tubules rénaux/effets des médicaments et des substances chimiques , Tubules rénaux/métabolisme , Tubules rénaux/anatomopathologie , Facteurs inhibiteurs de la migration des macrophages/sang , Souris , Myoglobine/métabolisme , Myoglobine/toxicité , Oxydoréduction , Agents protecteurs/administration et posologie , Espèces réactives de l'oxygène/métabolisme , Thiorédoxines/administration et posologie
4.
Biochem Pharmacol ; 97(3): 310-9, 2015 Oct 01.
Article de Anglais | MEDLINE | ID: mdl-26232728

RÉSUMÉ

Red blood cell (RBC) transfusions for controlling hemorrhaging induce systemic ischemia reperfusion, resulting in a decrease in hepatic cytochrome P450 (CYP) levels. Carbon monoxide (CO), when bound to red blood cells (CO-RBC) has the potential to protect the hepatic CYP protein to produce a resuscitative effect in a hemorrhagic shock rat model. The aim of this study was to investigate the mechanism by which CO-RBC resuscitation from a massive hemorrhage protects against a decrease in hepatic CYP. In the early phase (∼1h) after a hemorrhage and RBC resuscitation, hepatic CYP protein levels were significantly decreased with increasing hepatic free heme levels, but were maintained by a pre-treatment of gadolinium chloride (GdCl3), a Kupffer cell inhibitor, and Trolox, an anti-oxidant agent, as well as CO-RBC resuscitation. Under these conditions, the production of reactive oxygen species (ROS) derived from activated Kupffer cells was increased, but this increase was suppressed by CO-RBC resuscitation. At a late phase (6∼24h), CYP mRNA levels decreased after hemorrhage and RBC resuscitation, but not in the case of CO-RBC resuscitation. The increases in plasma IL-6 and TNF-α levels were decreased by CO-RBC resuscitation via the suppression of the toll-like receptor-4 (TLR-4) and the expression of the high mobility group box-1 (HMGB-1). Hepatic CYP protection after a hemorrhage and CO-RBC resuscitation can be attributed to the inactivation of Kupffer cells, resulting in the suppression of ROS production in the early phase and the suppression of inflammatory cytokine production via the TLR-4/HMGB-1signal pathway in the late phase.


Sujet(s)
Antioxydants/pharmacologie , Monoxyde de carbone/pharmacologie , Cytochrome P-450 enzyme system/métabolisme , Cytokines/immunologie , Érythrocytes/effets des médicaments et des substances chimiques , Protéine HMGB1/métabolisme , Cellules de Küpffer/effets des médicaments et des substances chimiques , Foie/effets des médicaments et des substances chimiques , Choc hémorragique/prévention et contrôle , Récepteur de type Toll-4/métabolisme , Animaux , Chromanes/pharmacologie , Cytokines/sang , Transfusion d'érythrocytes/effets indésirables , Transfusion d'érythrocytes/méthodes , Gadolinium/pharmacologie , Foie/enzymologie , Activation des macrophages/effets des médicaments et des substances chimiques , Mâle , Midazolam/sang , Midazolam/pharmacocinétique , Midazolam/pharmacologie , Rat Sprague-Dawley , Choc hémorragique/sang , Choc hémorragique/enzymologie , Choc hémorragique/immunologie
5.
J Pharm Sci ; 104(11): 3968-3976, 2015 Nov.
Article de Anglais | MEDLINE | ID: mdl-26249543

RÉSUMÉ

A preclinical study of dodecapeptide ((400)HHLGGAKQAGDV(411)) (H12)-(adenosine diphosphate, ADP)-liposomes for use as a synthetic platelet (PLT) substitute under conditions of red blood cell (RBC) transfusion-induced dilutional thrombocytopenia is limited to pharmacological effect. In this study, the pharmacokinetics of H12-(ADP)-liposomes in RBC transfusion-induced dilutional thrombocytopenic rats were evaluated. As evidenced by the use of (14) C, (3) H double-radiolabeled H12-(ADP)-liposomes in which the encapsulated ADP and liposomal membrane were labeled with (14) C and (3) H, respectively, the H12-(ADP)-liposomes remained intact in the blood circulation for up to 3 h after injection, and were mainly distributed to the liver and spleen. The encapsulated ADP was mainly eliminated in the urine, whereas the outer membrane was mainly eliminated in the feces. These successive pharmacokinetic properties of the H12-(ADP)-liposomes in RBC transfusion-induced dilutional thrombocytopenic rats were similar to those in healthy rats, except for the shorter retention time in the circulation. When H12-(ADP)-liposomes were repeatedly injected into RBC transfusion-induced dilutional thrombocytopenic rats at intervals of 5 days at a dose of 10 mg lipids/kg, the second dose of injected H12-(ADP)-liposomes were rapidly cleared from the circulation, namely, via the accelerated blood clearance phenomenon. These novel pharmacokinetic findings provide useful information for the further development of H12-(ADP)-liposomes as a PLT substitute.


Sujet(s)
ADP/pharmacocinétique , Plaquettes/cytologie , Substituts sanguins/pharmacocinétique , Transfusion d'érythrocytes/effets indésirables , Oligopeptides/pharmacocinétique , Thrombopénie/étiologie , ADP/administration et posologie , ADP/analogues et dérivés , Séquence d'acides aminés , Animaux , Substituts sanguins/administration et posologie , Substituts sanguins/composition chimique , Modèles animaux de maladie humaine , Liposomes , Mâle , Oligopeptides/administration et posologie , Oligopeptides/composition chimique , Rats , Rat Sprague-Dawley , Thrombopénie/traitement médicamenteux
6.
J Pharm Sci ; 104(9): 3084-91, 2015 Sep.
Article de Anglais | MEDLINE | ID: mdl-25755009

RÉSUMÉ

Adenosine diphosphate (ADP)-encapsulated liposomes coated with a fibrinogen γ-chain dodecapeptide [H12 (dodecapeptide ((400) HHLGGAKQAGDV(411) ))-(ADP)-liposome] is a synthetic platelet substitute, in which the surface is covered with polyethylene glycol (PEG). It has been reported that repeated injections of PEGylated liposomes induce an accelerated blood clearance (ABC) phenomenon, which involves a loss in the long-circulation half-life of the material when administered repeatedly to the same animals. The objective of this study was to determine whether the ABC phenomenon was induced by repeated injections of H12-(ADP)-liposome in healthy and anticancer drug-induced thrombocytopenia model rats. The findings show that the ABC phenomenon was induced by healthy rats that were repeatedly injected with H12-(ADP)-liposomes at the interval of 5 days at a dose of 10 mg lipids/kg. The ABC phenomenon involves the production of anti-H12-(ADP)-liposome immunoglobulin M (IgM) and complement activation. On the other hand, when thrombocytopenia model rats were repeatedly injected with H12-(ADP)-liposomes under the same conditions, no ABC phenomenon, nor was any suppression of anti-H12-(ADP)-liposome IgM-mediated complement activation observed. We thus conclude that the repeated injection of H12-(ADP)-liposome treatment in rat model with anticancer drug-induced thrombocytopenia did not induce the ABC phenomenon.


Sujet(s)
ADP/administration et posologie , Antinéoplasiques/effets indésirables , Plaquettes/effets des médicaments et des substances chimiques , Substituts sanguins/administration et posologie , Fibrinogène/administration et posologie , Liposomes/administration et posologie , Animaux , Plaquettes/métabolisme , Période , Immunoglobuline M/métabolisme , Injections/méthodes , Mâle , Polyéthylène glycols/administration et posologie , Rats , Rat Sprague-Dawley , Thrombopénie/induit chimiquement
7.
J Pharm Sci ; 103(7): 2199-2206, 2014 Jul.
Article de Anglais | MEDLINE | ID: mdl-24890462

RÉSUMÉ

Red blood cell (RBC) transfusions are the gold standard in cases of massive hemorrhage, but induce hepatic ischemia-reperfusion injury, a serious complication associated with hemorrhage and RBC resuscitation. Thus, the development of a novel resuscitable fluid that is not associated with hepatic ischemia-reperfusion injury would be desirable. It was reported that exogenous carbon monoxide (CO) treatment ameliorated hepatic ischemia-reperfusion injury accompanying liver transplantation. This suggests that transfusions with CO-bound RBC (CO-RBC) might protect against hepatic ischemia-reperfusion injury following massive hemorrhage and resuscitation compared with RBC resuscitation. To investigate this, we created a hemorrhagic shock model rat, followed by resuscitation with RBC and CO-RBC. Hepatic ischemia-reperfusion injury and the destruction of hepatic cytochrome P450 (CYP) were significantly ameliorated in the CO-RBC resuscitation group compared with the RBC resuscitation group. The free heme derived from the destruction of hepatic CYP was correlated with hepatic oxidation and injury, suggesting that CO-RBC was a major factor in the amelioration of hepatic ischemia-reperfusion injury induced by hemorrhage and resuscitation via hepatic CYP protection. These results indicate that CO-RBC has potential for use as a resuscitative fluid in blood transfusion and does not suffer from the limitations associated with the RBC transfusions that are currently in use.


Sujet(s)
Monoxyde de carbone/sang , Cytochrome P-450 enzyme system/métabolisme , Transfusion d'érythrocytes/effets indésirables , Érythrocytes/métabolisme , Foie/vascularisation , Lésion d'ischémie-reperfusion/prévention et contrôle , Choc hémorragique/thérapie , Animaux , Dapsone/sang , Dapsone/pharmacocinétique , Modèles animaux de maladie humaine , Transfusion d'érythrocytes/méthodes , Hème/métabolisme , Foie/enzymologie , Foie/métabolisme , Tests de la fonction hépatique , Mâle , Stress oxydatif , Rat Sprague-Dawley , Espèces réactives de l'oxygène/métabolisme , Lésion d'ischémie-reperfusion/enzymologie , Lésion d'ischémie-reperfusion/étiologie , Réanimation , Choc hémorragique/complications , Choc hémorragique/enzymologie
8.
Drug Metab Dispos ; 41(8): 1584-91, 2013 Aug.
Article de Anglais | MEDLINE | ID: mdl-23735758

RÉSUMÉ

Fibrinogen γ-chain (dodecapeptide HHLGGAKQAGDV, H12)-coated, ADP-encapsulated liposomes [H12-(ADP)-liposomes] were developed as a synthetic platelet alternative that specifically accumulates at bleeding sites as the result of interactions with activated platelets via glycoprotein IIb/IIIa and augments platelet aggregation by releasing ADP. The aim of this study is to characterize the pharmacokinetic properties of H12-(ADP)-liposomes and structural components in rats, and to predict the blood retention of H12-(ADP)-liposomes in humans. With use of H12-(ADP)-liposomes in which the encapsulated ADP and liposomal membrane cholesterol were radiolabeled with (14)C and (3)H, respectively, it was found that the time courses for the plasma concentration curves of (14)C and (3)H radioactivity showed that the H12-(ADP)-liposomes remained intact in the blood circulation for up to 24 hours after injection, and were mainly distributed to the liver and spleen. However, the (14)C and (3)H radioactivity of H12-(ADP)-liposomes disappeared from organs within 7 days after injection. The encapsulated ADP was metabolized to allantoin, which is the final metabolite of ADP in rodents, and was mainly eliminated in the urine, whereas the cholesterol was mainly eliminated in feces. In addition, the half-life of the H12-(ADP)-liposomes in humans was predicted to be approximately 96 hours from pharmacokinetic data obtained for mice, rats, and rabbits using an allometric equation. These results suggest that the H12-(ADP)-liposome has potential with proper pharmacokinetic and acceptable biodegradable properties as a synthetic platelet substitute.


Sujet(s)
ADP/administration et posologie , Substituts sanguins/administration et posologie , Fibrinogène/administration et posologie , Oligopeptides/administration et posologie , ADP/composition chimique , Animaux , Relation dose-effet des médicaments , Fibrinogène/composition chimique , Fibrinogène/pharmacocinétique , Humains , Liposomes , Mâle , Souris , Lapins , Rats , Rat Sprague-Dawley , Distribution tissulaire
9.
Drug Metab Dispos ; 41(1): 141-8, 2013 Jan.
Article de Anglais | MEDLINE | ID: mdl-23077106

RÉSUMÉ

Red blood cell (RBC) transfusions for massive hemorrhage induce systemic ischemic-reperfusion and influence the disposition and pharmacological activity of drugs as a result of a reduction in the level of expression and activity of cytochrome P450s (P450). It was reported that, when organ-preserving solutions are exposed to carbon monoxide (CO), the treatment was effective in suppressing the postreperfusion reduction in renal P450 levels in cases of kidney transplantation. Therefore, we hypothesized that transfusions with RBC that contain bound CO (CO-RBC) would protect the hepatic level of rat P450 during a massive hemorrhage, compared with plasma expanders and RBC resuscitation. To achieve this, we created 40% hemorrhagic-shock model rats, followed by resuscitation, with use of recombinant human serum albumin, RBCs, and CO-RBCs. At 1 hour after resuscitation, the expressions of hepatic P450 isoforms (1A2, 2C11, 2E1, and 3A2) were significantly decreased in the RBC resuscitation group, compared with the sham group. Such alterations in hepatic P450 significantly resulted in an increase in the plasma concentrations of substrate drugs (caffeine [1A2], tolbutamide [2C11], chlorzoxazone [2E1], and midazolam [3A2]) for each P450 isoform, and thus, the hypnotic action of midazolam could be significantly prolonged. Of interest, the reductions in hepatic P450 activity observed in the RBC group were significantly suppressed by CO-RBC resuscitation, and consequently, the pharmacokinetics of substrate drugs and the pharmacological action of midazolam remained at levels similar to those under sham conditions. These results indicate that CO-RBC resuscitation has considerable potential in terms of achieving safe and useful drug therapy during massive hemorrhages.


Sujet(s)
Monoxyde de carbone/sang , Cytochrome P-450 enzyme system/métabolisme , Transfusion d'érythrocytes/effets indésirables , Foie/enzymologie , Choc hémorragique/thérapie , Animaux , Technique de Western , Mâle , Midazolam/pharmacologie , Rats , Rat Sprague-Dawley , Choc hémorragique/enzymologie
10.
Life Sci ; 91(11-12): 420-428, 2012 Oct 05.
Article de Anglais | MEDLINE | ID: mdl-22935405

RÉSUMÉ

AIMS: Liposome-encapsulated hemoglobin (hemoglobin vesicles: HbV; diameter 250 nm) is reconstructed from human hemoglobin and developed as an artificial oxygen carrier for use as a transfusion alternative. Previous studies using rodent models closely investigated the safety of daily repeated infusions (DRI) of HbV and reported that the reticuloendothelial system was physiologically capable of degrading HbV to maintain plasma clinical chemistry within normal ranges. The present study examined the effect of DRI of HbV on the pregnant rat mother and fetal development, focusing on placental transfer of HbV in pregnancy. MAIN METHODS: Pregnant rats intravenously received HbV bolus injections at 2 ml/kg/day for the last 7 consecutive days till term. The cumulative infusion volume (14 ml/kg) was equal to 25% of the whole blood volume (56 ml/kg). KEY FINDINGS: Maternal DRI of HbV had no obvious side effects on the pregnant mother or on fetal development. Maternal vital signs, plasma clinical chemistry, and blood gas parameters were overall normal after DRI of HbV. In addition, maternal/fetal transfer of HbV was limited to the placenta and HbV did not reach the fetus. Histopathological examination with human hemoglobin antibody detected HbV accumulation in the maternal spleen, liver, kidney, and placenta, but not in the fetuses. These results were also confirmed by a pharmacokinetic study using (125)I-labeled HbV. SIGNIFICANCE: This safety study of HbV use in the pregnant mother and fetus will contribute to a possible application of HbV as a potential treatment for fetal hypoxia by supplying oxygen through the placenta.


Sujet(s)
Hémoglobines/administration et posologie , Échange foetomaternel , Animaux , Femelle , Développement foetal , Foetus/composition chimique , Hémoglobines/analyse , Hémoglobines/métabolisme , Humains , Perfusions veineuses , Rein/composition chimique , Liposomes , Foie/composition chimique , Placenta/composition chimique , Grossesse , Rats , Rat Wistar , Rate/composition chimique
11.
J Pharmacol Exp Ther ; 337(1): 201-8, 2011 Apr.
Article de Anglais | MEDLINE | ID: mdl-21228067

RÉSUMÉ

Hemoglobin vesicles (HbVs) could serve as a substitute for red blood cells (RBCs) in resuscitation from massive hemorrhage. A massive transfusion of RBCs can increase the risk of infection, which is not caused by contaminating micro-organisms in the transfused RBCs but by a breakdown of the host defense system. We previously found that complement activity was increased after resuscitation with HbVs at a putative dose in a rat model of hemorrhagic shock. It is known that complement system plays a key role in host defense in the embryonic stage. Therefore, the objective of this study was to address whether the suppression of bacterial infections in hemorrhagic shock rats was a result of increased complement activity after massive HbV transfusion. For this purpose, Escherichia coli were incubated with plasma samples obtained from a rat model of hemorrhagic shock resuscitated by HbVs or RBCs, and bacterial growth was determined under ex vivo conditions. As a result, E. coli growth was found to be suppressed by increased complement activity, mediated by the production of IgM from spleen. However, this antibacterial activity disappeared when the E. coli were treated with complement-inactivated plasma obtained from splenoctomized rats. In addition, the resuscitation of HbVs from hemorrhagic shock increased the survival rate and viable bacterial counts in blood in cecum ligation and puncture rats, a sepsis model. In conclusion, the resuscitation of HbVs in the rat model of hemorrhagic shock suppresses bacterial growth via complement activation induced by IgM.


Sujet(s)
Activation du complément/physiologie , Modèles animaux de maladie humaine , Escherichia coli/croissance et développement , Traitement par apport liquidien/méthodes , Hémoglobines/pharmacologie , Choc hémorragique/traitement médicamenteux , Animaux , Activation du complément/effets des médicaments et des substances chimiques , Escherichia coli/effets des médicaments et des substances chimiques , Hémoglobines/usage thérapeutique , Rats , Rat Sprague-Dawley , Choc hémorragique/microbiologie , Vésicules de transport/microbiologie , Vésicules de transport/physiologie
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE